Posch D, et al. – Experts probed gender–specific aspects in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT). This study suggested that prognosis and baseline characteristics were identical. Moreover, there appeared no differences between female and male patients with MM undergoing ASCT.

Methods

• They regulated a retrospective data analysis of 191 patients with MM who underwent ASCT.
• Age, sex, stage, induction therapy, outcome of induction, kind of stem cell mobilization, response to induction therapy and ASCT, cytogenetic aberrations, progression-free survival, and overall survival were included in data collected from clinical records.

Results

• This study incorporated eighty-one female patients (42%), and 110 male patients (58%).
• As per the international staging system (ISS) (e.g., ISS III: 14.8 vs. 17.3%), type of paraprotein, and cytogenetic aberrations (e.g., Del(13q): 32.7 vs. 28.9%), no differences between female and male patients could be observed.
• When calculated from time to ASCT until death, five-year overall survival rates, were 27.2 and 36.4% and, when calculated from time to diagnosis until death, were 34.6 and 44.5%.
• These rates did not differ between groups according to ISS subgroups.